1. Home /
  2. Biotechnology

Biotechnology

2 Downtrodden Small Biotechs That Are Showing Signs of Life

2 Downtrodden Small Biotechs That Are Showing Signs of Life

T2 Biosystems and Replimune Group have spurted higher in the last couple weeks, with the former doubling in value on encouraging news.

Positive Developments for These 3 Biotech Stocks

Positive Developments for These 3 Biotech Stocks

We review Acadia Pharmaceuticals, The Medicines Company, and Flexion Therapeutics.

If You're Not Allergic to Risk, Consider Aimmune Therapeutics on Strength

If You're Not Allergic to Risk, Consider Aimmune Therapeutics on Strength

AIMT lacks a strong and developed base, so only small long positions should be bought.

Eli Lilly's Must-Hold Level on Drug-Data Pullback

Eli Lilly's Must-Hold Level on Drug-Data Pullback

Eli Lilly stock is falling on the day after releasing clinical trial data. Here's the must-hold spot for LLY stock now.

Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment

Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment

Acadia Pharmaceuticals rockets higher after it announces it has ended a phase 3 trial of its dementia-related psychosis treatment, pimavanserin, on better-than-expected results.

These 2 Biotech Stocks Are Seeing Insider Buying Activity

These 2 Biotech Stocks Are Seeing Insider Buying Activity

We're focused on Progenics Pharmaceuticals and Aerie Pharmaceuticals.

Eli Lilly's Lung Cancer Treatment Candidate Shows Strong Results in Trial

Eli Lilly's Lung Cancer Treatment Candidate Shows Strong Results in Trial

Lilly acquired the drug as part of its $8 billion acquisition of Loxo Oncology.

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.

There's Value In These 2 Small Beaten Down Biotech Stocks

There's Value In These 2 Small Beaten Down Biotech Stocks

Both stocks have seen some recent insider buying.

AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer

AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer

Rova-T failed to show a survival benefit for patients when compared with a placebo.